Sclx stock price forecast the sclx stock price forecast considers

The sclx stock price forecast considers both technical patterns and sector trends. Biotech ETFs inflow is rising, often correlated with small-cap healthcare stocks gaining traction in momentum-driven markets. According to the 4 industry analysts covering Scilex Holding, the consensus is that breakeven is near. They expect the company to post a final loss in 2024, before turning a profit of US$41m in 2025. Therefore, the company is expected to breakeven roughly 12 months from now or less. How fast will the company have to grow to reach the consensus forecasts that anticipate breakeven by 2025? Working backwards from analyst estimates, it turns out that they expect the company to grow 54% year-on-year, on average, which signals high confidence from analysts. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict. On June 23, 2025, Scilex Holding Company announced the deferral of the record date for its previously announced dividend of Series 1 Mandatory Exchangeable Preferred Stock from May 2, 2025, to a future date yet to be determined by the Board of Directors. This decision allows the Board to retain flexibility in determining the new record date and potentially revoking the dividend, impacting stakeholders by introducing uncertainty regarding the timing and payment of the dividend. Traders are watching MACD indicators for crossover signals that could trigger upward momentum next week.